Omega-3 Supplementation and Outcomes of Heart Failure: A Systematic Review of Clinical Trials

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2024 Jan 19

PMID 38241565

Authors

Mahin Nomali

Mohammad Eghbal Heidari

Aryan Ayati

Amirhossein Tayebi

Oksana Shevchuk

Ramin Mohammadrezaei

Hossein Navid

Sayyed Saeid Khayyatzadeh

Svitlana Palii

Fahimeh Valizade Shiran

Atie Sadat Khorasanian

Zahra Veysi

Atena Jamalzehi

Azadeh Lesani

Golnoosh Assari

Shiva Khani

Kamyab Hassanpour

Hadis Gerami

Affiliations

Soon will be listed here.

Abstract

Backgrounds: Omega-3 supplements are endorsed for heart failure (HF) patients to reduce hospitalizations and mortality, offering anti-inflammatory and cardioprotective benefits.

Methods: A comprehensive search was conducted in various databases until November 2022. Eligible studies included clinical trials on patients with HF. Data extraction covered study details, omega-3 specifics, outcomes, and limitations. The JADAD scale was used to assess the risk of bias in randomized controlled trials.

Results: The review process involved 572 records from database searches, resulting in 19 studies after eliminating duplicates and screening. These studies assessed the impact of omega-3 on various clinical outcomes, such as mortality, hospitalization, cardiac function, and quality of life. Studied duration varied from weeks to years. Omega-3 supplementation demonstrated potential benefits such as improved heart function, reduced inflammation, and decreased risk of cardiovascular events.

Conclusion: Omega-3 supplementation could benefit heart disease treatment, potentially reducing therapy duration and improving outcomes. Starting omega-3 supplementation for HF patients seems favorable.

Citing Articles

Unveiling the Lipid Features and Valorization Potential of Atlantic Salmon () Heads.

Monteiro J, Sousa T, Melo T, Pires C, Marques A, Nunes M Mar Drugs. 2024; 22(11).

PMID: 39590798 PMC: 11595946. DOI: 10.3390/md22110518.

Role of ACSBG1 in Brain Lipid Metabolism and X-Linked Adrenoleukodystrophy Pathogenesis: Insights from a Knockout Mouse Model.

Ye X, Li Y, Gonzalez-Lamuno D, Pei Z, Moser A, Smith K Cells. 2024; 13(20.

PMID: 39451204 PMC: 11506745. DOI: 10.3390/cells13201687.

Inflammation and resolution in obesity.

Sotak M, Clark M, Suur B, Borgeson E Nat Rev Endocrinol. 2024; 21(1):45-61.

PMID: 39448830 DOI: 10.1038/s41574-024-01047-y.

The Key Role of Nutritional Intervention in Delaying Disease Progression and the Therapeutic Management of Diabetic Kidney Disease-A Challenge for Physicians and Patients.

Peride I, Anastasiu M, Serban S, Tiglis M, Ene R, Nechita A J Pers Med. 2024; 14(8).

PMID: 39201970 PMC: 11355100. DOI: 10.3390/jpm14080778.

Blood metabolites mediate effects of breakfast skipping on heart failure via Mendelian randomization analysis.

Lv L, Guo Y, Zheng Z, Li B Sci Rep. 2024; 14(1):18957.

PMID: 39147796 PMC: 11327247. DOI: 10.1038/s41598-024-69874-7.

References

Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A . Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation. 1995; 92(6):1479-86. DOI: 10.1161/01.cir.92.6.1479. View

Djousse L, Cook N, Kim E, Walter J, Al-Ramady O, Luttmann-Gibson H . Diabetes Mellitus, Race, and Effects of Omega-3 Fatty Acids on Incidence of Heart Failure Hospitalization. JACC Heart Fail. 2022; 10(4):227-234. PMC: 8986092. DOI: 10.1016/j.jchf.2021.12.006. View

Collins N, Tighe A, Brunton S, Kris-Etherton P . Differences between dietary supplement and prescription drug omega-3 fatty acid formulations: a legislative and regulatory perspective. J Am Coll Nutr. 2009; 27(6):659-66. DOI: 10.1080/07315724.2008.10719743. View

Wurm R, Schrutka L, Hammer A, Moertl D, Berger R, Pavo N . Polyunsaturated fatty acids supplementation impairs anti-oxidant high-density lipoprotein function in heart failure. Eur J Clin Invest. 2018; 48(9):e12998. PMC: 6175474. DOI: 10.1111/eci.12998. View

Selvaraj S, Bhatt D, Steg P, Miller M, Brinton E, Jacobson T . Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE-IT. J Am Heart Assoc. 2022; 11(7):e024999. PMC: 9075460. DOI: 10.1161/JAHA.121.024999. View

Emmons-Bell S, Johnson C, Roth G . Prevalence, incidence and survival of heart failure: a systematic review. Heart. 2022; 108(17):1351-1360. PMC: 9380485. DOI: 10.1136/heartjnl-2021-320131. View

Siddiqui W, Kohut A, Hasni S, Goldman J, Silverman B, Kelepouris E . Readmission rate after ultrafiltration in acute decompensated heart failure: a systematic review and meta-analysis. Heart Fail Rev. 2017; 22(6):685-698. DOI: 10.1007/s10741-017-9650-3. View

Radaelli A, Cazzaniga M, Viola A, Balestri G, Janetti M, Signorini M . Enhanced baroreceptor control of the cardiovascular system by polyunsaturated Fatty acids in heart failure patients. J Am Coll Cardiol. 2006; 48(8):1600-6. DOI: 10.1016/j.jacc.2006.05.073. View

Sakamoto A, Saotome M, Iguchi K, Maekawa Y . Marine-Derived Omega-3 Polyunsaturated Fatty Acids and Heart Failure: Current Understanding for Basic to Clinical Relevance. Int J Mol Sci. 2019; 20(16). PMC: 6719114. DOI: 10.3390/ijms20164025. View

10.

Chia N, Fulcher J, Keech A . Beta-blocker, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, nitrate-hydralazine, diuretics, aldosterone antagonist, ivabradine, devices and digoxin (BANDAID(2) ): an evidence-based mnemonic for the treatment of systolic heart.... Intern Med J. 2015; 46(6):653-62. DOI: 10.1111/imj.12839. View

11.

Rattarasarn I, Yingchoncharoen T, Assavapokee T . Prediction of rehospitalization in patients with acute heart failure using point-of-care lung ultrasound. BMC Cardiovasc Disord. 2022; 22(1):330. PMC: 9310393. DOI: 10.1186/s12872-022-02781-9. View

12.

Thierer J, Acosta A, Vainstein N, Sultan M, Francesia A, Marino J . Relation of left ventricular ejection fraction and functional capacity with metabolism and inflammation in chronic heart failure with reduced ejection fraction (from the MIMICA Study). Am J Cardiol. 2010; 105(7):977-83. DOI: 10.1016/j.amjcard.2009.11.017. View

13.

Mori T, Beilin L . Omega-3 fatty acids and inflammation. Curr Atheroscler Rep. 2004; 6(6):461-7. DOI: 10.1007/s11883-004-0087-5. View

14.

Angkananard T, Anothaisintawee T, Eursiriwan S, Gorelik O, McEvoy M, Attia J . The association of serum magnesium and mortality outcomes in heart failure patients: A systematic review and meta-analysis. Medicine (Baltimore). 2016; 95(50):e5406. PMC: 5268025. DOI: 10.1097/MD.0000000000005406. View

15.

Parish S, Mafham M, Offer A, Barton J, Wallendszus K, Stevens W . Effects of Omega-3 Fatty Acid Supplements on Arrhythmias. Circulation. 2020; 141(4):331-333. DOI: 10.1161/CIRCULATIONAHA.119.044165. View

16.

OKeefe Jr J, Abuissa H, Sastre A, Steinhaus D, Harris W . Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions. Am J Cardiol. 2006; 97(8):1127-30. DOI: 10.1016/j.amjcard.2005.11.025. View

17.

Nodari S, Metra M, Milesi G, Manerba A, Cesana B, Gheorghiade M . The role of n-3 PUFAs in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy. Cardiovasc Drugs Ther. 2008; 23(1):5-15. DOI: 10.1007/s10557-008-6142-7. View

18.

Calder P . Dietary fatty acids and the immune system. Lipids. 1999; 34 Suppl:S137-40. DOI: 10.1007/BF02562264. View

19.

Feltner C, Jones C, Cene C, Zheng Z, Sueta C, Coker-Schwimmer E . Transitional care interventions to prevent readmissions for persons with heart failure: a systematic review and meta-analysis. Ann Intern Med. 2014; 160(11):774-84. DOI: 10.7326/M14-0083. View

20.

Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D . Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996; 17(1):1-12. DOI: 10.1016/0197-2456(95)00134-4. View